BEIJING, Aug 9 (Reuters) - Sinopharm unit China National

Medicines on Friday said it does not have any

business dealings or relations with Shanxi Osteorad Biomaterial

Co, according to a filing to the Shanghai Stock Exchange.

Shanxi Osteorad is suspected of illegally purchasing human

remains and limbs to be used as raw materials for the production

of "allogeneic bone implantable materials", government-backed

media The Paper reported previously.